Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

SUNPHARMA's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 2.570000
forwardPE 29.042746
debtToEquity 6.675000
earningsGrowth 0.024000
revenueGrowth 0.089000
grossMargins 0.781920
operatingMargins 0.232560
trailingEps 43.570000
forwardEps 56.189590

SUNPHARMA's current ratio of 2.57 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, SUNPHARMA can comfortably cover its liabilities, reflecting a strong financial outlook.
Sun Pharmaceutical Industries Limited's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
Sun Pharmaceutical Industries Limited's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
Sun Pharmaceutical Industries Limited's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in Sun Pharmaceutical Industries Limited's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

Sun Pharmaceutical Industries Limited's stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


Analysts' buy bias toward Sun Pharmaceutical Industries Limited suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Sun Pharmaceutical Industries Limited is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.